Actively Recruiting
Visual (Path)Ways in Multiple Sclerosis - Part II
Led by University Hospital, Lille · Updated on 2025-01-31
64
Participants Needed
1
Research Sites
65 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Multiple sclerosis (MS) is an inflammatory demyelinating and degenerative disease of the central nervous system. The mechanisms of neuro-axonal loss remain incompletely elucidated. An acute demyelinating lesion will produce both immediate and delayed axonal loss. Immediate axonal loss is linked to the occurrence of axonal transection. Delayed axonal loss is the cause of axonal degeneration in progressive MS. Visual impairment is common in the disease (vision, oculomotricity, cognition). Through a longitudinal multimodal analysis of visual pathways, we would like to investigate physiopathological mechanisms leading to neurodegenerative process and visual impairment.
CONDITIONS
Official Title
Visual (Path)Ways in Multiple Sclerosis - Part II
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female participants from the VWIMS research project
- At least 18 years old at the time of inclusion in VWIMS - II
- Written consent given to participate in the study
- Socially insured patient
- Willing to comply with all study procedures and duration
- Patients with relapsing-remitting multiple sclerosis receiving high-efficacy or non-high-efficacy treatment and previously followed at the CRCSEP of Lille University Hospital through VWIMS study participation
You will not qualify if you...
- Under 18 years old
- Other neurological conditions affecting MRI or OCT data such as diabetes, any cause of retinopathy, glaucoma, retinal detachment, or ametropia greater than 6 diopters
- Contraindications to MRI including claustrophobia, incompatible metal foreign bodies (e.g., certain pacemakers, mechanical valves, cochlear implants, intra-orbital metal splinters), pregnancy, or certain IUD brands
- Contraindications to injection such as severe renal failure with creatinine clearance under 30, allergy to contrast media, pregnancy, or breastfeeding
- Pregnant or nursing women
- Unable to give consent independently or under legal protection
- Persons deprived of liberty
- Administrative reasons such as inability to receive informed information, inability to participate fully, lack of social security coverage, or refusal to sign consent form
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Direction de la Recherche et de l'innovation (DRI) 6 rue Professeur Laguesse
Lille, France, 59037
Actively Recruiting
Research Team
O
OUTTERYCK Olivier, PhD
CONTACT
C
COURTOIS Brigitte
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here